Author:
Soares Heloisa P.,Bayraktar Soley,Blaya Marcelo,Lopes Gilberto,Merchan Jaime,Macintyre Jessica,Mayo Carlos,Green Mark R.,Silva Orlando,Levi Joe,Walker Gail,Rocha-Lima Caio M.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference24 articles.
1. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-20132013 . Accessed 4 Sept 2013
2. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825
3. Von Hoff DD, Ervin T, Arena FP, Gabriela Chiorean E, Infante JR, Moore MJ et al (2013) Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates. In: ASCO annual meeting. Chicago, IL. J Clin Oncol 31: abstract 4005
4. Oettle H, Pelzer U, Stieler J et al (2005) Oxaliplatin/folinic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-pretreated advanced pancreatic cancer (CONKO 003). In: ASCO annual meeting proceedings 2005. J Clin Oncol 23: abstract 4031
5. Pelzer U, Kubica K, Stieler J et al (2008) A randomized trial in patients with gemcitabine pretreated pancreatic cancer. Final results of the CONKO 003 study. In: ASCO annual meeting proceedings. J Clin Oncol 26: abstract 4508
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献